# Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

> **NCT00103428** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cell Genesys** · enrollment: 69 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** CG7870

## Key facts

- **NCT ID:** NCT00103428
- **Lead sponsor:** Cell Genesys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 69 (—)
- **Last updated:** 2006-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103428, "Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00103428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*